BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 38542096)

  • 1. The Role of Sodium-Glucose Co-Transporter-2 Inhibitors on Diuretic Resistance in Heart Failure.
    Stachteas P; Nasoufidou A; Patoulias D; Karakasis P; Karagiannidis E; Mourtzos MA; Samaras A; Apostolidou X; Fragakis N
    Int J Mol Sci; 2024 Mar; 25(6):. PubMed ID: 38542096
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of Sodium-Glucose Cotransporter-2 Inhibitors in Clinical Practice for Heart Failure Prevention and Treatment: Beyond Type 2 Diabetes. A Narrative Review.
    Rao S
    Adv Ther; 2022 Feb; 39(2):845-861. PubMed ID: 34881413
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of sodium glucose co-transporter inhibitors in heart failure prevention.
    Garla V; Subauste A; Butler J; Lien LF
    J Diabetes Complications; 2021 Mar; 35(3):107811. PubMed ID: 33280983
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of sodium-glucose co-transporter-2 inhibitors by background cardiovascular medications: A systematic review and meta-analysis.
    Avgerinos I; Karagiannis T; Matthews DR; Tsapas A; Bekiari E
    Diabetes Obes Metab; 2023 Oct; 25(10):3020-3029. PubMed ID: 37435776
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prescribing sodium-glucose co-transporter-2 inhibitors for type 2 diabetes in primary care: influence of renal function and heart failure diagnosis.
    Hinton W; Feher MD; Munro N; Joy M; de Lusignan S
    Cardiovasc Diabetol; 2021 Jun; 20(1):130. PubMed ID: 34183018
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sodium-glucose cotransporter-2 inhibitors in heart failure: Potential decongestive mechanisms and current clinical studies.
    Biegus J; Fudim M; Salah HM; Heerspink HJL; Voors AA; Ponikowski P
    Eur J Heart Fail; 2023 Sep; 25(9):1526-1536. PubMed ID: 37477086
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of sodium-glucose co-transporter-2 inhibitors in patients with and without type 2 diabetes: implications for incident and prevalent heart failure.
    Butler J; Handelsman Y; Bakris G; Verma S
    Eur J Heart Fail; 2020 Apr; 22(4):604-617. PubMed ID: 31926059
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Eligibility of sodium-glucose co-transporter-2 inhibitors among patients with diabetes mellitus admitted for heart failure.
    Sharma A; Wu J; Ezekowitz JA; Felker GM; Udell JA; Heidenreich PA; Fonarow GC; Mahaffey KW; Hernandez AF; DeVore AD
    ESC Heart Fail; 2020 Feb; 7(1):274-278. PubMed ID: 31747132
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sodium glucose cotransporter 2 inhibitors as diuretic adjuvants in acute decompensated heart failure: a case series.
    Griffin M; Riello R; Rao VS; Ivey-Miranda J; Fleming J; Maulion C; McCallum W; Sarnak M; Collins S; Inzucchi SE; Testani JM
    ESC Heart Fail; 2020 Aug; 7(4):1966-1971. PubMed ID: 32476296
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of GLP-1 receptor agonists and SGLT-2 inhibitors on cardiac structure and function: a narrative review of clinical evidence.
    Natali A; Nesti L; Tricò D; Ferrannini E
    Cardiovasc Diabetol; 2021 Sep; 20(1):196. PubMed ID: 34583699
    [TBL] [Abstract][Full Text] [Related]  

  • 11. What Makes Sodium-Glucose Co-Transporter-2 Inhibitors Stand out in Heart Failure?
    Khan MS; Vaduganathan M
    Curr Diab Rep; 2020 Oct; 20(11):63. PubMed ID: 33040170
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sodium-glucose co-transporter-2 inhibitors and major adverse limb events: A trial-level meta-analysis including 51 713 individuals.
    Huang CY; Lee JK
    Diabetes Obes Metab; 2020 Dec; 22(12):2348-2355. PubMed ID: 32744411
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of sodium glucose cotransporter-2 (SGLT-2) inhibitors in heart failure and chronic kidney disease in type 2 diabetes.
    Woo V; Connelly K; Lin P; McFarlane P
    Curr Med Res Opin; 2019 Jul; 35(7):1283-1295. PubMed ID: 30767677
    [No Abstract]   [Full Text] [Related]  

  • 14. Cardiovascular protective effect of sodium-glucose cotransporter 2 inhibitors on patients with acute coronary syndrome and type 2 diabetes mellitus: a retrospective study.
    Chen J; Chang J; Shi Q; Li X; Wang L; Zhao H
    BMC Cardiovasc Disord; 2023 Oct; 23(1):495. PubMed ID: 37805494
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association between sodium glucose co-transporter 2 inhibitors and a reduced risk of heart failure in patients with type 2 diabetes mellitus: a real-world nationwide population-based cohort study.
    Kim YG; Han SJ; Kim DJ; Lee KW; Kim HJ
    Cardiovasc Diabetol; 2018 Jun; 17(1):91. PubMed ID: 29935543
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current Perspectives of the Use of Sodium-Glucose Transport-2 Inhibitors for Patients With Heart Failure and Chronic Kidney Disease.
    Vider E; Sapir R; Mosseri E; Gavioli E
    J Cardiovasc Pharmacol; 2022 Mar; 79(3):247-253. PubMed ID: 34775428
    [TBL] [Abstract][Full Text] [Related]  

  • 17. European Society of Cardiology/Heart Failure Association position paper on the role and safety of new glucose-lowering drugs in patients with heart failure.
    Seferović PM; Coats AJS; Ponikowski P; Filippatos G; Huelsmann M; Jhund PS; Polovina MM; Komajda M; Seferović J; Sari I; Cosentino F; Ambrosio G; Metra M; Piepoli M; Chioncel O; Lund LH; Thum T; De Boer RA; Mullens W; Lopatin Y; Volterrani M; Hill L; Bauersachs J; Lyon A; Petrie MC; Anker S; Rosano GMC
    Eur J Heart Fail; 2020 Feb; 22(2):196-213. PubMed ID: 31816162
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Therapeutic Role of SGLT-2 Inhibitors in Acute Heart Failure: From Pathophysiologic Mechanisms to Clinical Evidence with Pooled Analysis of Relevant Studies across Safety and Efficacy Endpoints of Interest.
    Patoulias D; Fragakis N; Rizzo M
    Life (Basel); 2022 Dec; 12(12):. PubMed ID: 36556427
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of sodium-glucose co-transporter (SGLT)-2 inhibitors in heart failure management and implications for the kidneys.
    Lioudaki E; Joslin JR; Trachanatzi E; Androulakis E
    Rev Cardiovasc Med; 2022 Mar; 23(3):82. PubMed ID: 35345249
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of SGLT-2 inhibitors on cardiovascular outcomes in heart failure patients: A meta-analysis of randomized controlled trials.
    Lu Y; Li F; Fan Y; Yang Y; Chen M; Xi J
    Eur J Intern Med; 2021 May; 87():20-28. PubMed ID: 33824055
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.